Fundraising Fox
Tvardi Therapeutics
NASDAQ: TVRDHouston, US · Founded 2017 · Delaware corporation · 20 employees on LinkedIn · 2 known investors
Find your way into Tvardi Therapeutics
Sign up to see every warm intro you have to Tvardi Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tvardi Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule STAT3 inhibitors to treat inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in a Phase 2 trial for hepatocellular carcinoma, and TTI-109, a phosphate prodrug of TTI-101.
Founders & leadership
Tvardi Therapeutics was founded in 2017 by David J. Tweardy.
DJ
David J. TweardyFounder
JW
Joseph W. StaufferExecutive
FM
Frederique MenzaghiExecutive
IA
Imran AlibhaiChief Executive OfficerImran Alibhai is Chief Executive Officer of Tvardi Therapeutics, a clinical-stage biopharmaceutical company developing STAT3 inhibitors for inflammatory and proliferative diseases. He has held executive, advisory, and investment roles across public and private life sciences companies.
RD
Ronald DePinhoNamed on SEC filing
IA
Imran Alibhai, Ph.D.Chief Executive Officer
Board
MV
Martin VogelbaumBoard director
JL
Jeffrey L. IvesBoard director
DS
Dean SlagelBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$78.2M disclosed across 3 rounds · 2014–2021
▶$72.4MraisedJun 2021 · 32 investors · BiotechnologyRule 506(b)
▶$72.4MraisedJun 2021 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jamie McNabDirector
- Michael WyzgaDirector
- Wallace HallDirector
- Imran AlibhaiExecutive Officer, Director
- Sujal ShahDirector
- Offering amount
- $75.1M
- Amount sold
- $72.4M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.6MraisedJul 2018 · 8 investors · PharmaceuticalsRule 506(b)
▶$5.6MraisedJul 2018 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ronald DePinhoDirector
- David J. TweardyExecutive Officer, Director
- Offering amount
- $8.5M
- Amount sold
- $5.6M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$100KraisedDec 2014 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedDec 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Josef SchoellExecutive Officer
- Jeffrey L. IvesDirector
- Joseph W. StaufferExecutive Officer
- Derek ChalmersExecutive Officer, Director
- Michael E. LewisExecutive Officer
- Martin VogelbaumDirector
- Dean SlagelDirector
- Frederique MenzaghiExecutive Officer
- Harrison BainsDirector
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies working in the same space as Tvardi Therapeutics.
In the news
Frequently asked questions
- What does Tvardi Therapeutics do?
- Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule STAT3 inhibitors to treat inflammatory and proliferative diseases. Its pipeline includes TTI-101, a direct STAT3 inhibitor in a Phase 2 trial for hepatocellular carcinoma, and TTI-109, a phosphate prodrug of TTI-101.
- Who founded Tvardi Therapeutics?
- Tvardi Therapeutics was founded by David J. Tweardy in 2017.
- Who are Tvardi Therapeutics's investors?
- Tvardi Therapeutics's investors include ShangBay Capital LLC, Solas BioVentures.
- How much funding has Tvardi Therapeutics raised?
- Tvardi Therapeutics has disclosed $78.2M raised across 3 rounds.
- Where is Tvardi Therapeutics headquartered?
- Tvardi Therapeutics is headquartered in Houston, US.